Table 2.
Comparison of ASCP to PDAC populations
| Study | Data source | No. Of patients | Poor diff (%) | Node-positive (%) | Tumor size (cm) | Median OS (mo) | OS (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | ASCP | PDAC | Time | ||
| [79] | SEER | 415 (0.9%) | 45693 | 71.4 | 45 | 52.8 | 47.1 | 5.7 | 4.3 | 4 | 5 | 10.8 | 10.9 | 2y |
| [80] | NCDB | 1745 (0.8%) | 205328 | 40.6 | 17.3 | 21.9 | 14.8 | 56%* | 33.1%* | 5.7 | 6.2 | 13 | 13.8 | 2y |
| [81] | CA Cancer Reg | 95 (0.6%) | 14746 | 4 | NR | |||||||||
Digits in italics indicate the study found a statistically significant difference in this measure.
*
Indicates measurement of percent tumors ≥ 4 cm. Poor diff: Poorly differentiated tumor on histology; OS: overall survival; NR: not reported.